Jobs with high IPF mortality ratios differed by sex, but notable categories for both included the public administration industry and health care practitioners and technical occupations, according to ...

Idiopathic pulmonary fibrosis is a progressive and life-threatening lung disease but there are ASX companies bringing hope to ...

According to a recent study, roughly one in five of idiopathic pulmonary fibrosis deaths might be related to occupational exposures.

Qureight and Remedy Cell have collaborated to validate the mechanism of action of RC-0315 in the Phase Ib clinical trial for treating idiopathic pulmonary fibrosis (IPF). The trial’s primary objective ...

Pliant Therapeutics, Inc. (Nasdaq: PLRX) today announced that following a prespecified data review and recommendation by the ...

Pliant Therapeutics discontinued its BEACON-IPF trial for bexotegrast due to safety concerns but observed early efficacy. The ...

Pliant issued a press release "announc[ing] that following a prespecified data review and recommendations by the trial's ...

IPF is a fatal, highly complex and progressive interstitial lung disease affecting approximately 3 million people worldwide. With a median survival of only 2-5 years post-diagnosis, it is ...

Idiopathic pulmonary fibrosis is a progressive and life-threatening lung disease but there are ASX companies bringing hope to sufferers. Characterised by the thickening and scarring of lung tissue ...